RapidPulse Raises $48 Million Series B To Advance Stroke Aspiration Technology

July 19, 2026 - 10:00

RapidPulse has closed a $48 million Series B funding round to push forward its aspiration technology designed for treating acute ischemic stroke. The company announced that the financing was oversubscribed, reflecting strong investor interest in its approach to removing blood clots from the brain.

The round was co-led by Medtronic, TechWald Next, and S3 Ventures. Additional participants included SBI Investment Company and the Florida Opportunity Fund. Existing backers such as Santé Ventures, Syntheon, Hatteras Venture Partners, and Epidarex Capital also joined the round.

The company plans to use the capital to support clinical development of its RapidPulse Cyclic Aspiration System. This system uses a high-frequency, pulsed vacuum to remove clots more efficiently than standard continuous suction methods. Early data suggests the technology could reduce procedure times and improve recanalization rates in patients suffering from large vessel occlusion strokes.

Stroke remains a leading cause of disability worldwide, and rapid removal of clots is critical for patient outcomes. The new funding will allow RapidPulse to expand its clinical trials and prepare for potential regulatory submissions. The involvement of Medtronic, a major player in the neurovascular space, signals confidence in the technology's potential to become a standard tool in thrombectomy procedures.